M&A Deal Summary |
|
|---|---|
| Date | 2020-11-30 |
| Target | Takeda Pharmaceutical Co. - Primary Care Product Assets |
| Sector | Life Science |
| Buyer(s) | Celltrion |
| Sellers(s) | Takeda |
| Deal Type | Divestiture |
| Deal Value | 278M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Life Science |
| Employees | 2,391 |
| Revenue | 3.56T KRW (2024) |
Celltrion is a biopharmaceutical company specializing in the development of “biosimilars” for monoclonal antibody drugs. Celltrion provides biosimilars for auto-immune diseases and various cancers; generic pharmaceuticals; and covid-19 test kits. Celltrion was founded in 2002 and is based in Incheon, South Korea.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Japan M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-11-14 |
iQone
Versoix, Switzerland iQone is a specialty pharmaceutical company focused on distribution, sales, and marketing. iQone was founded in 2013 and is based in Versoix, Switzerland. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1781 |
| Sector | Life Science |
| Employees | 47,455 |
| Revenue | 4.58T JPY (2025) |
Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was established in 1781 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 6 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 6 of 6 |
| Country: Japan M&A | 5 of 5 |
| Year: 2020 M&A | 3 of 3 |
| Size (of disclosed) | 3 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-16 |
TachoSil
Osaka, Japan TachoSil provides surgical patches used for bleeding control. |
Sell | $564M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-03-09 |
Maverick Therapeutics
Brisbane, California, United States Maverick Therapeutics is a biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies. Maverick Therapeutics provides T cell therapy to solid tumor cancers by focusing deep integrated expertise in drug development to design and deliver a pioneering immunotherapy platform. Maverick’s highly innovative COBRA™ therapeutic platform is the most mature, conditionally active bispecific T cell engaging platform designed to eliminate solid tumors. With COBRA, T cell activation and resulting cell killing only take place where it is needed – in tumors. This unique design delivers the long-sought trifecta in cancer care; high specificity, high potency, and reduced toxicity. Maverick Therapeutics was founded in 2016 and is based in Brisbane, California. |
Buy | $525M |
